
Loading, please wait...

Loading, please wait...

The 2022 ERS/ATS technical standard provides a modern framework for interpreting routine pulmonary function tests. It addresses how clinicians should assess spirometry, lung volumes and diffusing capacity rather than interpreting an isolated number in isolation. The document emphasizes use of appropriate reference equations, recognition of patterns and integration of multiple measurements with the clinical context. It also updates the approach to defining abnormality and supports standardized terminology for reporting lung-function results. The practical value is substantial because pulmonary function testing is often used to confirm or refine diagnoses, characterize severity and follow disease over time. An apparently abnormal FEV1/FVC ratio, restrictive-looking pattern or reduced DLCO should therefore trigger a structured interpretation rather than an automatic diagnostic label. The standard fits directly with the NAPCON PFT workshop and symposium, particularly the emphasis on lung volumes, DLCO and practical interpretation beyond FEV1/FVC. For HCPs, it reinforces a simple principle: reliable interpretation depends on technically sound testing, appropriate reference ranges and pattern recognition. This publication is especially useful as a foundation for multidisciplinary discussions involving pulmonology, radiology and other clinicians managing complex breathlessness.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The 2022 ERS/ATS technical standard provides a modern framework for interpreting routine pulmonary function tests. It addresses how clinicians should assess spirometry, lung volumes and diffusing capacity rather than interpreting an isolated number in isolation. The document emphasizes use of appropriate reference equations, recognition of patterns and integration of multiple measurements with the clinical context. It also updates the approach to defining abnormality and supports standardized terminology for reporting lung-function results. The practical value is substantial because pulmonary function testing is often used to confirm or refine diagnoses, characterize severity and follow disease over time. An apparently abnormal FEV1/FVC ratio, restrictive-looking pattern or reduced DLCO should therefore trigger a structured interpretation rather than an automatic diagnostic label. The standard fits directly with the NAPCON PFT workshop and symposium, particularly the emphasis on lung volumes, DLCO and practical interpretation beyond FEV1/FVC. For HCPs, it reinforces a simple principle: reliable interpretation depends on technically sound testing, appropriate reference ranges and pattern recognition. This publication is especially useful as a foundation for multidisciplinary discussions involving pulmonology, radiology and other clinicians managing complex breathlessness.
Today

The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back

A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back

Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back

A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back

A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back